 BASEL, Switzerland, Jan. 20, 2021 GLOBE NEWSWIRE -- Myovant Sciences NYSE: MYOV, a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards to David Marek in connection with his previously-announced employment by Myovant Sciences, Inc. MSI as its chief executive officer, which consisted of restricted stock units RSUs to acquire 223,076 common shares of Myovant Sciences Ltd. Myovant, and an option to purchase 306,427 Myovant common shares. In addition, Myovant granted RSUs to acquire an aggregate of up to 87,300 Myovant common shares to eight other new employees joining MSI. The equity awards were granted to Mr. Marek and the other employees on January 15, 2021 under the 2020 Inducement Plan in accordance with NYSEs Listed Company Manual Rule 303A.08. 